Takeda Publishes Promising Trial Results on Ixazomib, an Approved Drug to Treat Relapsed Multiple Myeloma
Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination…